植物及植物來源藥物：全球市場

全球植物及植物來源藥物市場預計將從 2025 年的 387 億美元成長到 2030 年底的 581 億美元，預測期內複合年成長率為 8.5%。

預計亞太地區市場規模將從2025年的131億美元成長到2030年底的208億美元，預測期內複合年成長率為9.6%。預計歐洲市場規模將從2025年的117億美元成長到2030年底的175億美元，預測期內複合年成長率為8.3%。

本報告考察了全球植物藥和植物來源藥物市場，並提供了市場概況、市場影響因素和市場機會分析、技術趨勢、法律制度、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

目錄

第1章執行摘要

• 市場展望
• 調查範圍
• 市場摘要
• 概述
• 當前市場情勢
• 細分市場分析
• 新興技術
• 結論

第2章 市場概覽

• 概述
• 植物來源的歷史
• 古埃及治療方法（約西元前1500年）
• 傳統中醫（古代）
• 傳統藥局中的植物來源產品
• 奎寧：一種治療瘧疾的突破性藥物，提取自金雞納樹（17世紀）
• 阿斯匹靈：一種源自柳樹皮的藥物（19世紀）
• 植物藥價值鏈
• 耕作與收穫
• 主要治療
• 監管、製造和消費者
• 宏觀經濟因素分析
• 人口統計因素
• 地緣政治因素
• 美國關稅的影響
• 波特五力分析

第3章 市場動態

• 市場動態
• 市場促進因素
• 消費者對天然療法的偏好正在改變
• 良好的安全性和耐受性
• 萃取、純化和分析技術的進步
• 人口老化和慢性病日益增多
• 支持性的法規結構
• 市場限制
• 配置複雜且缺乏標準化
• 植物藥研發經費不足
• 市場機遇
• 植物代謝物在藥物發現的應用
• 生物技術在個人化醫療發展的應用日益廣泛

第4章：監理現狀

• 概述
• 美國
• 歐洲
• 其他國家

第5章 新興科技與發展

• 重點總結
• 單體學方法
• 多體學方法
• 發酵技術
• 管道分析
• 重點總結

第6章 市場區隔分析

• 細分市場分析
• 按產品類型分類的市場分析
• 重點總結
• 植物藥
• 植物來源藥物
• 按應用領域進行市場分析
• 重點總結
• 癌症
• 心血管疾病
• 中樞神經系統疾病
• 感染疾病
• 其他
• 地理細分
• 區域市場分析
• 北美洲
• 歐洲
• 亞太地區
• 世界其他地區

第7章 競爭訊息

• 重點總結
• 競爭分析
• 大型製藥企業
• 植物藥公司
• 策略舉措

8. 植物及植物來源藥物市場的永續性：ESG視角

• ESG簡介
• 植物及植物來源藥物產業的永續性趨勢與舉措
• 結論

第9章附錄

• 調查方法
• 來源
• 首字母縮寫詞
• 公司簡介
• ANI PHARMACEUTICALS INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• CHIESI FARMACEUTICI SPA
• FRESENIUS KABI AG
• GSK PLC
• JAGUAR HEALTH
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• MALLINCKRODT
• MEDIWOUND
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• 新興Start-Ups/市場顛覆者

The global market for botanical and plant-derived drugs is expected to grow from $38.7 billion in 2025 and is projected to reach $58.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2025 to 2030.

The Asia-Pacific market for botanical and plant-derived drugs is expected to grow from $13.1 billion in 2025 and is projected to reach $20.8 billion by the end of 2030, at a CAGR of 9.6% during the forecast period of 2025 to 2030.

The European market for botanical and plant-derived drugs is expected to grow from $11.7 billion in 2025 and is projected to reach $17.5 billion by the end of 2030, at a CAGR of 8.3% during the forecast period of 2025 to 2030.

Report Scope

The report provides an overview of the global market for botanical and plant-derived drugs and analyzes market trends. It includes global revenue ($ million) for 2024 as the base year data and estimated data for the forecast period, which is 2025 through 2030. The market is segmented based on product, application and region. By type, the market is segmented into plant-derived drugs and botanicals.

This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.

This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.

Report Includes

• 47 data tables and 47 additional tables
• An overview of the global market for botanical and plant-derived drugs
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the botanical and plant-derived drugs, accompanied by a market share analysis by type, application and region
• Analysis of current and future demand in the botanical and plant-derived drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Detailed information on some of the botanical or plant products that have received FDA approval for prescription medications, such as Veregen and Fulyzaq, and a discussion of their therapeutic advantages over synthetic substitutes
• Analysis of drivers, challenges and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
• Profiles of major companies within the industry, including Bayer, Novartis, Jaguar Health Inc., Jazz Pharmaceuticals, and Bristol Myers Squibb Co.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Emerging Technologies
• Conclusion

Chapter 2 Market Overview

• Overview
• History of Plant-Derived Medicines
• Ancient Egyptian Healing Practices (Circa 1500 BCE)
• Chinese Herbal Medicine (Ancient times)
• Plant-Derived Products in the Traditional Pharmacopeias
• Quinine: A Malaria Breakthrough from Cinchona (17th Century)
• Aspirin: A Gift from the Willow Tree (19th Century)
• Botanical Drugs Value Chain
• Cultivation and Collection
• Primary Processing
• Regulatory, Manufacturing and Consumers
• Macroeconomic Factors Analysis
• Demographic Factors
• Geopolitical Factors
• Impact of U.S. Tariffs
• Porter's Five Forces Analysis
• Potential of New Entrants: Moderate to High
• Bargaining Power of Suppliers: Moderate to High
• Bargaining Power of Buyers: Moderate
• Threat of Substitute Products or Services: Moderate
• Level of Competitiveness: High

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Shift in Consumer Preference for Natural-Origin Therapeutics
• Favorable Safety and Tolerability Profile
• Advances in Extraction, Purification, and Analytical Technologies
• Aging Population and the Growing Prevalence of Chronic Diseases
• Supportive Regulatory Frameworks
• Market Restraints
• Complex Composition and Lack of Standardization
• Lack of Funding for Botanical Drugs R&D
• Market Opportunities
• Application of Plant Metabolites for Drug Discovery
• Growing Biotechnological Integration for Personalized Medicine Development

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Other Countries

Chapter 5 Emerging Technologiesand Developments

• Key Takeaways
• Single-Omics Approaches
• Multi-Omics Approaches
• Fermentation Technology
• Pipeline Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Product Type
• Key Takeaways
• Botanical Drugs
• Plant-Derived Drugs
• Market Analysis by Application
• Key Takeaways
• Cancer
• Cardiovascular Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Others
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Analysis
• Large Pharmaceutical Companies
• Botanical Drug Companies
• Strategic Initiatives

Chapter 8 Sustainability in the Botanical and Plant-Derived Drugs Market: An ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives of the Botanical and Plant-Derived Drugs Industry
• Concluding Remarks

Chapter 9 Appendix

• Research Methodology
• Sources
• Acronyms
• Company Profiles
• ANI PHARMACEUTICALS INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• CHIESI FARMACEUTICI S.P.A.
• FRESENIUS KABI AG
• GSK PLC
• JAGUAR HEALTH
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• MALLINCKRODT
• MEDIWOUND
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 1 : Important Natural Products Derived from Plants
• Table 2 : Global Incidence and Mortality Cancer Rates, by WHO Region, 2022
• Table 3 : Natural Products Classified as Medicines in Different Jurisdictions
• Table 4 : EU Regulation of Herbal Medicinal Products
• Table 5 : Regulation of Herbal Medicinal Products
• Table 6 : Botanical Drugs in Development
• Table 7 : Global Market for Botanical and Plant-Derived Drugs, by Product Type, Through 2030
• Table 8 : Global Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 9 : Global Market for Cancer Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 10 : Global Market for Cardiovascular Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 11 : Global Market for Central Nervous System Disorder Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 12 : Global Market for Infectious Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 13 : Global Market for Other Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 14 : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 15 : North American Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 16 : North American Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
• Table 17 : U.S. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 18 : Canadian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 19 : Mexican Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 20 : European Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 21 : European Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
• Table 22 : Percentage of Indications for Using Herbal Medicines in Germany
• Table 23 : German Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 24 : U.K. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 25 : French Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 26 : Spanish Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 27 : Italian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 28 : Rest of Europe Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 29 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 30 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
• Table 31 : Chinese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 32 : Japanese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 33 : Indian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 34 : South Korean Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 35 : Rest of Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 36 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 37 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Sub-Region, Through 2030
• Table 38 : Strategic Initiatives in the Botanical and Plant-Derived Drugs Market, 2021-2025
• Table 39 : Information Sources in this Report
• Table 40 : Abbreviations Used in the Botanical and Plant-Derived Drugs Market
• Table 41 : ANI Pharmaceuticals Inc.: Company Snapshot
• Table 42 : ANI Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 43 : ANI Pharmaceuticals Inc.: Product Portfolio
• Table 44 : Bayer AG: Company Snapshot
• Table 45 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 46 : Bayer AG: Product Portfolio
• Table 47 : Bayer AG: News/Recent Developments, 2024-2025
• Table 48 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 49 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 50 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 51 : CHIESI Farmaceutici S.p.A.: Company Snapshot
• Table 52 : CHIESI Farmaceutici S.p.A.: Financial Performance, FY 2023 and 2024
• Table 53 : CHIESI Farmaceutici S.p.A.: Product Portfolio
• Table 54 : CHIESI Farmaceutici S.p.A.: News/Key Developments, 2023
• Table 55 : Fresenius Kabi AG: Company Snapshot
• Table 56 : Fresenius Kabi AG: Financial Performance, FY 2023 and 2024
• Table 57 : Fresenius Kabi AG: Product Portfolio
• Table 58 : GSK plc: Company Snapshot
• Table 59 : GSK plc: Financial Performance, FY 2023 and 2024
• Table 60 : GSK plc: Product Portfolio
• Table 61 : GSK plc: News/Key Developments, 2022
• Table 62 : Jaguar Health: Company Snapshot
• Table 63 : Jaguar Health: Financial Performance, FY 2023 and 2024
• Table 64 : Jaguar Health: Product Portfolio
• Table 65 : Jaguar Health: News/Key Developments, 2023-2025
• Table 66 : Jazz Pharmaceuticals Inc.: Company Snapshot
• Table 67 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 68 : Jazz Pharmaceuticals Inc.: Product Portfolio
• Table 69 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2021
• Table 70 : Johnson & Johnson: Company Snapshot
• Table 71 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
• Table 72 : Johnson & Johnson: Product Portfolio
• Table 73 : Mallinckrodt: Company Snapshot
• Table 74 : Mallinckrodt: Financial Performance, FY 2023 and 2024
• Table 75 : Mallinckrodt: Product Portfolio
• Table 76 : MediWound: Company Snapshot
• Table 77 : MediWound: Financial Performance, FY 2023 and 2024
• Table 78 : MediWound: Product Portfolio
• Table 79 : MediWound: News/Key Developments, 2022-2024
• Table 80 : Novartis AG: Company Snapshot
• Table 81 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 82 : Novartis AG: Product Portfolio
• Table 83 : Novartis AG: News/Key Developments, 2024
• Table 84 : Pfizer Inc.: Company Snapshot
• Table 85 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 86 : Pfizer Inc.: Product Portfolio
• Table 87 : Sanofi: Company Snapshot
• Table 88 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 89 : Sanofi: Product Portfolio
• Table 90 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 91 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 92 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 93 : List of a Few Emerging Startups in the Botanical and Plant-Derived Drugs Market

List of Figures

• Summary Figure : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
• Figure 1 : Botanical Drugs Value Chain
• Figure 2 : Porter's Five Forces Analysis of the Botanical and Plant-Derived Drugs Market
• Figure 3 : Market Dynamics of Botanical and Plant-Derived Drugs
• Figure 4 : Global Market Shares of Botanical and Plant-Derived Drugs, by Product Type, 2024
• Figure 5 : Global Market Shares of Botanical and Plant-Derived Drugs, by Application Type, 2024
• Figure 6 : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
• Figure 7 : North American Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
• Figure 8 : European Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
• Figure 9 : Asia-Pacific Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
• Figure 10 : Rest of the World Market Shares of Botanical and Plant-Derived Drugs, by Sub-Region, 2024
• Figure 11 : ANI Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 12 : ANI Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 13 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
• Figure 14 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
• Figure 15 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 16 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 17 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Business Unit, FY 2024
• Figure 18 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Country/Region, FY 2024
• Figure 19 : Fresenius Kabi AG: Revenue Shares, by Business Unit, FY 2024
• Figure 20 : GSK plc: Revenue Shares, by Business Unit, FY 2024
• Figure 21 : GSK plc: Revenue Shares, by Country/Region, FY 2024
• Figure 22 : Jaguar Health: Revenue Shares, by Business Unit, FY 2024
• Figure 23 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 24 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 25 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
• Figure 26 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
• Figure 27 : Mallinckrodt: Revenue Shares, by Business Unit, FY 2024
• Figure 28 : Mallinckrodt: Revenue Shares, by Country/Region, FY 2024
• Figure 29 : MediWound: Revenue Shares, by Country/Region, FY 2024
• Figure 30 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 31 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 32 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 33 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 34 : Sanofi: Revenue Shares, by Country/Region, FY 2024
• Figure 35 : Teva Pharmaceutical Industries Ltd.: Market Shares, by Country/Region, FY 2024